CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults

Phase 1

Terminated

Conditions: Healthy

Interventions: Other: Placebo
Biological: CSL730

First Posted Date: 2017-12-18

Last Posted Date: 2021-06-03

Lead Sponsor: CSL Behring

Target Recruit Count: 26

Registration Number: NCT03375606

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands
🇬🇧
Hammersmith Medicines Research, London, United Kingdom

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Phase 3

Terminated

Conditions: Antibody-mediated Rejection

Interventions: Drug: Placebo
Drug: C1-esterase inhibitor

First Posted Date: 2017-07-19

Last Posted Date: 2022-07-29

Lead Sponsor: CSL Behring

Target Recruit Count: 63

Registration Number: NCT03221842

Locations: 🇺🇸
California Pacific, San Francisco, California, United States
🇺🇸
University of Illinois Chicago, Chicago, Illinois, United States
🇺🇸
St. Barnabas Medical Center, Livingston, New Jersey, United States

and more 23 locations

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Phase 4

Completed

Conditions: Primary Immunodeficiency

Interventions: Drug: IgPro20

First Posted Date: 2017-01-27

Last Posted Date: 2020-03-25

Lead Sponsor: CSL Behring

Target Recruit Count: 49

Registration Number: NCT03033745

Locations: 🇺🇸
Icahn Medical Institute, New York, New York, United States
🇨🇦
McGill University, Montréal, Quebec, Canada
🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada

and more 9 locations

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Phase 2

Completed

Conditions: Moderate Renal Impairment
Acute Myocardial Infarction

Interventions: Other: Placebo
Biological: CSL_112

First Posted Date: 2016-04-18

Last Posted Date: 2020-06-11

Lead Sponsor: CSL Behring

Target Recruit Count: 83

Registration Number: NCT02742103

Locations: 🇺🇸
Study Site 16168, Concord, California, United States
🇺🇸
Study Site 16135, Danbury, Connecticut, United States
🇮🇱
Study Site 19005, Haifa, Israel

and more 28 locations

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

Phase 4

Completed

Conditions: Primary Immune Deficiency
Secondary Immune Deficiency

Interventions: Biological: Subcutaneous Immune Globulin (Human) (Hizentra)

First Posted Date: 2016-03-17

Last Posted Date: 2018-02-26

Lead Sponsor: CSL Behring

Target Recruit Count: 26

Registration Number: NCT02711228

Locations: 🇨🇦
Centre Hospitalier de l'université de Montréal, Montreal, Canada
🇨🇦
CHU Sainte-Justine, Montreal, Canada

Study of Voncento® in Subjects With Von Willebrand Disease

Phase 4

Completed

Conditions: Von Willebrand Disease

Interventions: Biological: Voncento

First Posted Date: 2015-09-17

Last Posted Date: 2018-05-16

Lead Sponsor: CSL Behring

Target Recruit Count: 26

Registration Number: NCT02552576

Locations: 🇬🇧
Study Site 40, London, United Kingdom
🇵🇱
Study Site, Wroclaw, Poland
🇬🇧
Study Site 14, London, United Kingdom

and more 3 locations

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Phase 2

Terminated

Conditions: Hemophilia A With Inhibitors
Hemophilia B With Inhibitors

Interventions: Drug: CSL689
Drug: Eptacog alfa (activated)

First Posted Date: 2015-06-29

Last Posted Date: 2019-08-28

Lead Sponsor: CSL Behring

Target Recruit Count: 25

Registration Number: NCT02484638

Locations: 🇬🇧
Site Reference # 8260008, London, United Kingdom
🇿🇦
Site Reference # 7100001, Johannesburg, South Africa
🇮🇹
Site Reference # 3800023, Milano, Italy

and more 7 locations

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Phase 1

Completed

Conditions: Congenital Coagulation Factor VII Deficiency

Interventions: Biological: Eptacog alfa (activated) or pdFVII
Biological: CSL689

First Posted Date: 2015-06-12

Last Posted Date: 2017-04-26

Lead Sponsor: CSL Behring

Target Recruit Count: 9

Registration Number: NCT02470871

Locations: 🇳🇴
Site Reference # 5780001, Oslo, Norway
🇳🇱
Site Reference 5280023, Njmegen, Netherlands

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

Completed

Conditions: Congenital Fibrinogen Deficiency

Interventions: Biological: FCH

First Posted Date: 2015-04-27

Last Posted Date: 2018-01-17

Lead Sponsor: CSL Behring

Target Recruit Count: 22

Registration Number: NCT02427217

Locations: 🇨🇦
Study Site, Montreal, Quebec, Canada

A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment

Phase 1

Completed

Conditions: Acute Myocardial Infarction

Interventions: Biological: CSL112
Other: Placebo

First Posted Date: 2015-04-27

Last Posted Date: 2017-09-19

Lead Sponsor: CSL Behring

Target Recruit Count: 32

Registration Number: NCT02427035

Locations: 🇩🇪
Study Site - 17101, Berlin, Germany
🇬🇧
Study Site - 24101, London, United Kingdom
🇩🇪
Study Site - 17102, Munich, Germany

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy